Status:
COMPLETED
A Evaluation of Systematic Intensive Therapy Using CGM/FGM in Clinical Diabetes Care
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Type1diabetes
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study aims to analyse if intensive systematic treatment via internet and telephone during 4 months improved HbA1c for persons with type 1 diabetes which are already treated with CGM or FGM, and i...
Eligibility Criteria
Inclusion
- Informed consent obtained before trial-related activities (i.e., any activity that would not have been performed during routine patient management)
- Clinical diagnosis of Type 1 diabetes
- Adult patients over 18 years of age
- HbA1c ≥ 58 mmol/mol
- Currently using CGM or FGM
- To have a possibility to download and share FGM/CGM data
Exclusion
- Type 2 diabetes
- Diabetes duration \<1 year
- Long-term Systemic glucocorticoid treatment during the last 3 months
- Planned or changed treatment the last 3 months regarding MDI vs. Insulin pump or added or stopped CGM or FGM therapy
- Current or planned pregnancy or breastfeeding during the next 12 months
- Planned move during the next 12 months making it not possible to participate in study activities
- Other reason determined by the investigator not being appropriate for participation
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT03474393
Start Date
November 1 2018
End Date
December 31 2023
Last Update
April 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NU-Hosptial Group
Uddevalla, Sweden